IRD
Opus Genetics Inc.

386
Mkt Cap
$128.27M
Volume
621,898.00
52W High
$2.37
52W Low
$0.65
PE Ratio
-1.08
IRD Fundamentals
Price
$1.98
Prev Close
$1.86
Open
$1.88
50D MA
$1.86
Beta
0.99
Avg. Volume
494,059.96
EPS (Annual)
-$2.15
P/B
20.12
Rev/Employee
$610,666.67
Loading...
Loading...
News
all
press releases
Opus Genetics FY2025 EPS Forecast Lifted by HC Wainwright
Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Equities researchers at HC Wainwright lifted their FY2025 earnings estimates for Opus Genetics in a research report issued on Thursday, November 13th...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
FY2025 Earnings Estimate for Opus Genetics Issued By Wedbush
Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Equities researchers at Wedbush boosted their FY2025 earnings per share estimates for Opus Genetics in a research report issued on Wednesday, November...
MarketBeat·3d ago
News Placeholder
HC Wainwright Comments on Opus Genetics Q1 Earnings
Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for Opus Genetics in a report released on Thursday, November 13th. HC...
MarketBeat·5d ago
News Placeholder
Opus Genetics (NASDAQ:IRD) Earns "Buy" Rating from Chardan Capital
Chardan Capital reissued a "buy" rating and issued a $9.00 target price on shares of Opus Genetics in a research report on Thursday...
MarketBeat·6d ago
News Placeholder
Opus Genetics (NASDAQ:IRD) Posts Earnings Results, Misses Expectations By $0.11 EPS
Opus Genetics (NASDAQ:IRD - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.11). The...
MarketBeat·7d ago
News Placeholder
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +14.29% and +11.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
Opus Genetics, Inc. Q3 Loss Misses Estimates
(RTTNews) - Opus Genetics, Inc. (IRD) released Loss for third quarter that missed the Street estimates...
Nasdaq News: Markets·8d ago
News Placeholder
Opus Genetics' (IRD) Buy Rating Reiterated at Chardan Capital
Chardan Capital reissued a "buy" rating and set a $9.00 price target on shares of Opus Genetics in a research report on Friday...
MarketBeat·12d ago
News Placeholder
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of +13.33% and -2.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for
Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·15d ago

Latest IRD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.